aneuploidy
Devyser Fetal Abnormality Test Nabs China Approval; Firm, Thermo Fisher Collaborate on FDA Approval
The fetal abnormality test measures the most common chromosomal abnormalities, including Down syndrome, via a single-tube PCR process.
BillionToOne Inks $140M Financing Agreement With Oberland Capital
The company said the funds will help it shore up its plans to reach profitability and supplant the need for additional financing rounds.
Devyser's Fetal Test Gains IVDR Certification
Devyser's QF-PCR-based test can be used by clinicians to detect aneuploidy in fetal cells circulating in maternal blood, amniotic fluid, and chorionic villus biopsy samples.
Natera Launches Tumor Genomic Profiling Assay, Expects Reproductive Health to Break Even This Year
Premium
During a conference call, company executives also discussed results from the SMART NIPT trial and their outlook for Natera's three businesses.
Natera Revenues Grow 35 Percent in Q4
The company reported $112.4 million in revenues compared to $83.2 million in Q4 2019, beating the average Wall Street estimate of $106.6 million.
Oct 26, 2020
Yourgene H1 Revenues Up 5 Percent
May 6, 2020
Natera Q1 Revenues Grow 41 Percent
Apr 20, 2020